Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Lung cancer remains a major global cause of cancer mortality.
• Traditional chemotherapy shows limited efficacy for advanced non-small cell lung cancer (NSCLC).
• Recent advancements in targeted therapies have improved NSCLC patient prognosis.

Purpose of the Study:

• To review the mechanisms and current status of targeted therapy for NSCLC.
• To discuss strategies for overcoming acquired resistance to targeted therapies.
• To address existing challenges in the field of NSCLC targeted therapy.

Main Methods:

• Review of existing literature on targeted therapies for NSCLC.
• Analysis of mechanisms of action for monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and tyrosine kinase inhibitors (TKIs).
• Examination of genetic targets such as EGFR and ALK in NSCLC.

Main Results:

• Targeted therapies, including mAbs, ADCs, and TKIs, offer improved outcomes for NSCLC patients.
• Understanding specific mutations like EGFR and ALK is crucial for effective targeted treatment.
• Acquired resistance remains a significant challenge, necessitating further research into overcoming it.

Conclusions:

• Targeted therapy represents a paradigm shift in NSCLC treatment, enhancing patient survival and quality of life.
• Continued research into resistance mechanisms and novel therapeutic strategies is essential.
• Personalized medicine approaches based on molecular profiling are key to optimizing NSCLC management.